Post My Press Release

Free Press Release Distribution

Category: Healthcare (Page 1 of 115)

Sugar-based Excipients Market Reflect Steady Growth Rate by 2026

An excipient is an inactive substance formulated with the active ingredient of a medication for the purpose of bulking-up Route of Administration that contain potent active ingredients. These substances improve bulkiness and dissolution rate of the drug and are crucial in drug delivery within the body. A sugar-based excipient is required if the conventional tablet contains a bitter drug substance or, more importantly, if the tablet is chewable. Sweeteners are added in tablets to impart sweetness to the drugs. Sucrose is the standard against, which all sweeteners, both artificial and natural, are measured. Apart from being sweeter than sucrose, artificial sweeteners have the advantage of not disturbing blood sugar levels of pre-diabetic or diabetic patients, and they are considered to be non-cariogenic. Sugar-based excipients are widely used as ingredients in pharmaceutical tableting. They are used for taste masking of bitter drugs and as bulking agents. Dextrose, fructose, mannitol, sorbitol, and xylitol are few examples of sugar-based excipients that are mainly used.

Ask For In-depth Sample Copy of Research Report at https://www.coherentmarketinsights.com/insight/request-sample/1653

Sugar-based Excipients Market Dynamics

Increasing use of co-processed excipients and rising development of orally disintegrating tablets (ODTs) are major factors that are expected to boost growth of sugar-based excipients market over the forecast period. ODTs are solid dosage forms containing medicinal substances, which disintegrate rapidly, generally in few seconds, when placed on the tongue. Research on delivering biological molecules through the oral route have widened the scope of ODT technology, which further drive growth of the market. According to the American Pharmaceutical Review 2016, over 35 products have been launched using Zydis ODT technology in over 60 countries worldwide. Furthermore, rising use of sugar alcohols such as mannitol in a wide range of oral dosage and high adaptability in formulation technologies such as ODTs are expected to drive the sugar-based excipients market growth over the forecast period. Sugar alcohol is granular and white like sugar, and is used as a sugar alternative. The sugar alcohols differ in calorie content and sweetness level. Their sweetness level ranges from 50% to 100% that of sugar.

Sugar-based Excipients Market Regional Insights

On the basis of region, the global sugar-based excipients market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America sugar-based excipients market is expected to hold a dominant position over the forecast period, owing to increased usage for generic drugs in the region. Increasing investments in drug development and rising production of generic drugs will drive growth of sugar-based excipient market in Europe. Significant growth in the healthcare and pharmaceutical industry, favorable government policies, low-cost manufacturing, and increasing demand for generic drugs, especially in emerging economies directly contributes to the market growth. According to the Food and Drug Administration (FDA) data, in 2017, Indian firms received around 40% of the new U.S. approvals for generics with a wider base of companies.

Sugar-based Excipients Market Competitive Landscape

Some of the key players operating in the global sugar-based excipients market include Ashland Inc., Associated British Foods Plc, BASF SE, Colorcon, Inc., Cargill, Inc., DFE Pharma, FMC Corporation, MEGGLE AG, Roquette Group, and The Lubrizol Corporation.

Sugar-based Excipients Market Taxonomy

On the basis of product, the sugar-based excipients market is segmented into:

  • Actual Sugars
  • Artificial Sweeteners
  • Sugar Alcohols

On the basis of excipient type, the sugar-based excipients market is segmented into:

  • Crystals
  • Direct Compression Sugars
  • Powders/granules
  • Syrups

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/sugar-based-excipients-market-1653

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Pompe Disease Therapeutic Market Analysis Showcases Growth Trends and Opportunity Forecast Until 2026

Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of enzyme acid named alpha-glucosidase (GAA). This causes the glycogen to accumulate in different kinds of tissues, primarily into smooth muscles, skeletal muscles and cardiac muscle. It leads to muscle weakness, respiratory problems, and may also affects the liver and heart. Pompe disease is inherited as an autosomal recessive genetic trait. There are three major types of pompe disease, which differ in severity and appear at different age, these types are known as classic infantile-onset, which starts within a few months of birth, non-classic infantile-onset Pompe disease- usually appears by age 1, and late-onset type of Pompe disease that may shows the symptoms later in childhood, adolescence, or adulthood. Pompe disease therapeutic market can exhibit immense growth potential due to presence of limited number of manufacturers, which can significantly enhance and expand their business potential and scope in this market.

Key players operating in the pompe disease therapeutic market include Amicus Therapeutics, Inc., Valerion Therapeutics, LLC, Sanofi S.A., Oxyrane, and Sangamo Therapeutics, Inc.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1316

Increasing government initiatives is expected to augment growth of the pompe disease therapeutic market

Considering the public health problems, government is taking continuous initiatives in promoting and advancing the development of innovative products for the prevention and diagnosis or treatment of rare diseases or conditions such as Pompe disease. For instance, in 2015, Orphan Product Grants Program funded 18 new grant awards from 92 grant applications and provided funding and support to around 67 ongoing clinical study projects related to rare disease. Furthermore, initiatives from the governments of economies such as Sweden, the Netherlands, and South Korea that focus on approving guidelines for the reimbursement of individuals undergoing enzyme replacement therapy (ERT) are also expected to boost growth of the pompe disease therapeutic market in near future.

Increasing prevalence of pompe disease in many economies is expected to have a lucrative opportunities for pharmaceutical manufacturers to come with a tailored solution for diagnosis and treatment of disease. For instance, according to United Pompe Foundation (UPF), 2017, the estimated frequency occurrence of Pompe disease may vary among different ethnic groups and nationalities: in Holland: 1 in 40,000 (Adults: 1 in 57,000; Infantile: 1 in 138,000), Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and Caucasian: 1 in 100,000 suffer from pompe disease. Gene therapy and enzyme replacement therapy may be highly effective at reducing clinical manifestations of this rare disease. Currently, there are two commercialized products in enzyme replacement therapy, which are Myozyme for the treatment of infants and children with Pompe disease and Lumizyme for late-onset non-infantile Pompe disease. Furthermore, various pipeline products in phase 3 (NeoGAA GZ402666 (Sanofi), AT-982 (Audentes therapeutics)) and in phase 2 (BMN 701(Biomarin)) clinical trial are also expected to create a meteoric growth in this market during the forecast period. However, the high cost associated with the treatment and long duration of the treatment are the factors restraining growth of the pompe disease therapeutic market. For instance, according to a research paper published by Harvard School, in 2016, Lumizyme accounted for US$ 100,000 per year for children and US$ 300,000 per year for adult treatments.

Increasing investments in research and development by manufacturers is expected to propel the market growth

Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for the treatment of Pompe disease. This novel treatment paradigm consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P) to enhance uptake, co-administered with AT2221, a pharmacological chaperone.

Click To Read More On Pompe Disease Therapeutic Market

Drug Discovery Informatics Market to Gain a Stronghold by 2026

Drug discovery informatics and development is an extremely complex process that involves generation of large volumes of data. At present the market for drug discovery informatics is largely unmet. The existing approaches to gather information from various sources have been dealt with in some cases where the data types are very least well-defined or largely homogeneous. Nonetheless, the world on the verge of a new age of drug discovery informatics, the methods and approaches in which are dealing with gathering information from data and knowledge from information are experiencing a paradigm shift. The demands of this industry are well defined: huge amounts of data are produced using various innovative technologies and the restraint is searching, integrating, and accessing this data. Additionally, the inclination is to make important development decisions in the early life cycle of the discovery process. It has become crucial to take care of these issues with the vast amount of data available from ongoing projects and also from early efforts of drug development. The future of drug discovery informatics will be the assimilation of distributed and heterogeneous data. Domain specific data mining and data integration such as genomic and chemical data will continue to offer significant opportunities for drug discovery informatics. Procurement and management of graphical, textual and undefined data are some of the challenges in this field. However, these will become a vital part of data searching as well as building knowledge and information-bases. These factors will eventually lead to the growth of the data discovery informatics market during the forecast period.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/224

Increasing chronic illnesses such as cancer, cardiovascular diseases (CVD), and diabetes mellitus is the chief concern for healthcare professionals and government organizations around the globe. The U.S. government in association with President’s Council of Advisors on Science and Technology (PCAST) has taken initiatives intended to improve financial stimulus to induce modernization in the pharmaceutical industry, which will drive the overall market for drug discovery informatics. Furthermore, collaborations amongst pharmaceutical companies have given rise to infusion of money and sharing of technologies amongst them, which has enabled these companies to develop local as well as global products.

Advent of technology and the increasing number of clinical trials will drive the overall drug discovery informatics market

With the advent of technology, innovative cloud-based and analytics technologies, storage and analysis of large amount of data is now possible at a lower cost. For example, Infosys popularized a cloud-based application to accelerate the management of data services for clinical trials. This in turn is likely to drive the whole drug design procedure. Infosys has been working in partnership with various clinical trial organizations and pharmaceutical companies to master the application and to provide easy access and management of data.

Top Key Players:

Some of the key players operating in the global drug discovery informatics market are Albany Molecular Research, GVK Biosciences, Infosys, Certara, ChemAxon, Jubilant Biosys, DiscoverX, Novo Informatics, Charles River Laboratories, Boehringer Ingelheim GmbH, and Selvita.

Drug Discovery Informatics market Taxonomy:

On the basis of mode, the global drug discovery informatics market is classified into:

– In-House Informatics

– Outsourced Informatics

On the basis of service segment, the global market is classified into:

– Sequence Analysis Platforms

– Molecular Modelling

– Docking

– Clinical Trial Data Management

– Others

On the basis of product segment, the global market is classified into:

• Discovery Informatics

– Identification & Validation Informatics Assay Development Informatics

– Lead Generation Informatics

• Development Informatics

– Lead Optimization

– FHD Preparation

– Phase IA Informatics

– Phase IB/2 Informatics

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/224

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

New Developments with Operational Updates in Myeloproliferative Neoplasms Treatment Market

Myeloproliferative Neoplasms (MPNs) are a group of rare disease, in which the bone marrow produces excess blood cells. It can be white blood cells, red blood cells or platelets. The overproduction of blood cells by the bone marrow creates hindrance in the smooth flow of blood, which leads to various symptoms such as progressive cytopenias, cachexia and weight loss, splenomegaly, and blastic transformation. These conditions are developed gradually over a period of time. Most people are diagnosed after the age of 60 years, when they were accompanied by many other health issues, makes the treatment more difficult.

The major symptoms associated with MPNs include bleeding problem, anemia, chest pain, fatigue, enlarged spleen, and weight loss. According to Annals of Hematology, approximately 90% of patients has experienced MPN-symptoms in past 12 months, wherein women are reported to have higher overall burden than men. The treatment for myeloproliferative neoplasms is mainly aimed to reduce the excess number of blood cells circulation. The concept of myleoproliferative disease was first given by hematologist Williom Dameshek in 1950. However, in 2008, World Health Organization (WHO) classified hematologic malignancies and renamed myloproliferative diseases to myeloproliferative neoplasms.

Request For a Sample Copy of This Research Report:https://www.coherentmarketinsights.com/insight/request-sample/930

Rising awareness of molecular abnormalities and cellular pathways involved in the pathogenesis of MPNs is expected to facilitate the development of novel drugs, propels the Myeloproliferative Neoplasms treatment market growth in the near future

Myeloproliferative neoplasm can significantly affect the quality of life of the patient. The complication and treatments as well as the physiological strains of cancer diagnosis can affect the physical and emotional wellbeing of patients. Effects of complication vary from depression, fatigue, pain or depression with suicidal ideation. Moreover, patients can experience few or no symptoms for a longer period of time. MPNs can be cured with proper monitoring and treatment. There has been a major revolution in the management of MPNs by introduction of JAK1 and JAK2 inhibitor and ruxolitinib. Ruxolitinib inhibits these two enzymes in order to manage MPNs. The drug has also been proven as an alternative therapy for the treatment of polycythemia vera. Further, the therapeutic armamentarium for MPN is still inadequate for normalization of life span, reduction in cardiovascular complications, and prevention of hematological progression.

Rising awareness of molecular abnormalities and cellular pathways involve in the pathogenesis of MPNs is expected to facilitate the development of clinical trials with novel drugs, either alone or in combination with ruxolitinib. Interferon (IFN) is a drug that has proven as an effective alternative for MPNs patients. Better understanding of its mechanism of action for MPNs could lead to better interferon compound and potential drugs. In 2017, MPN research foundation have initiated a MPNRF Interferon (IFN) multi-center project which is expected to bring together internationally recognized experts to determine cytokine-driven pathways that affect the path of the MPNs. It is a closely-related group of progressive blood cancer which is also among the lucrative opportunities for major players in the Myeloproliferative Neoplasms treatment market.

Collaboration among the biotech and pharmaceutical companies to identify new drugs for MPNs is expected to accelerate the market growth

Novartis AG and Incyte Corporation are among the key players in Myeloproliferative Neoplasms treatment market. According to MPN research foundation, biotech and pharmaceutical companies are expected to propel the demand for improved treatments and quickly connecting patients with latest treatment options. It is expected to lead developing relationships with biotech and pharmaceuticals companies to identify new areas for scientific exploration. For instance, Incyte Corporationis is developing inhibitor for Janus Kinase (JAK) and also focusing on the discovery, development, and commercialization of proprietary therapeutics globally.

Click To Read More On Myeloproliferative Neoplasms Treatment

Tacrolimus Market to Show Promising Growth Opportunities By 2026

Tacrolimus is used as an immunosuppressant mainly after organ transplant procedures to prevent organ rejection. Tacrolimus inhibits the activation of serine-threonine phosphatase, calcineurin, in T lymphocytes. This suppresses T lymphocyte activation and the subsequent generation of cytotoxic lymphocytes, thereby suppressing processes leading to organ rejection. Tacrolimus is primary immunosuppression drug used in kidney and liver transplant patients. Organ transplanted patients often require lifelong treatment with immunosuppressant. Major applications of this includes in cardiac transplant rejection, liver transplant rejection, kidney transplant rejection, and lung transplant immunosuppression treatment. Tacrolimus is available in various dosage forms such as tablets, capsules, and injections.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2298

Tacrolimus Market Drivers

Tacrolimus is majorly used as an immunosuppressant after organ transplant procedures. Advancement in organ transplant procedures is a major factor expected to increase the number of organ transplants, which in turn is expected to boost global tacrolimus market growth over the forecast period. For instance, new methods are being researched to match more donor organs with patients such as stem cell studies, trophic factor studies, and natural models. As the need for organ transplantation increases and the waiting list continues to grow, successful utilization and transplantation of as many available donor organs as possible has become important. According to Organ Procurement and Transplantation Network (OPTN) 117,000+ number of men, women, and children are on the national transplant waiting list as of July 2017 in the U.S. and 17,155 organ transplants are done so far in 2017.

Tacrolimus Market Regional Analysis

North America tacrolimus market is expected to dominate over the forecast period. Presence of leading manufacturers as well as high number of organ transplant procedures is expected to support global tacrolimus market growth. Regional generic manufacturers are focusing on providing generic version of tacrolimus formulations in developed as well emerging economies. For instance, Strides Arcolab received the U.S. Food & Drug Administration (FDA) approval for tacrolimus capsules to be used as immuno-suppressant in 2014. Sandoz launched Tacrolimus, a generic version of Astellas’s PROGRAF (tacrolimus) in Japan, in 2015. Moreover, The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for tacrolimus’ generic, Tacforius in 2017. These factors have supported the global tacrolimus market growth.

Tacrolimus Market Key Players

Key players operating in the global tacrolimus market include GlaxoSmithKline Plc, Abbott Laboratories, Novartis International AG, Mylan N.V., Astellas Pharma, Inc., Takeda Pharmaceuticals Company Ltd, Senju Pharmaceutical Co. Ltd., Guike Pharmaceutical Co. Ltd., DR. Reddy’s Laboratories Ltd., and Glenmark Pharmaceuticals Ltd.

Tacrolimus Market Taxonomy:

The global tacrolimus market is segmented on the basis of product type, application, end user, and region

By Product Type:

  • Tacrolimus Capsules and Tablets
  • Tacrolimus Ointment
  • Tacrolimus Injection

By Application:

  • Immunosuppression
  • Dermatitis
  • Others

Browse Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/tacrolimus-market-2298

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Ophthalmic Femtosecond Lasers Market Present Chances, Value Chain And Stakeholder Analysis 2018-2026

Femtosecond laser are ultrafast and ultrashort lasers that release optical pulses 10-15/seconds. The generation of short pulses are achieved by using the passive mode locking technique. This technique is used for generating pulses of light in very short duration (such as for picosecond or femtosecond durations). The femtosecond lasers are popular among ophthalmologists, as such devices help in simplifying and avoiding complex processes of open surgeries. Flap creation in laser in situ keratomileusis (LASIK) is the most common use of this type of laser. It can also be used for other corneal refractive procedures, cataract surgery, and lamellar and full thickness corneal transplantation.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/385

The femtosecond laser allows thin and uniform flaps that improve the stability, safety, and precision of the flaps. Added advantage of the femtosecond laser is that it allows the medical doctor to select the cutting angle, position, and diameter of the hinge, as well as the flap diameter and flap thickness, which may offer better flap stability and reduce clinical epithelial ingrowth.

According to Centre for Disease Control and Prevention (CDC), cataract is the prominent blinding condition in the 116 countries enclosed by the Blindness Data Bank in the World Health Organization (WHO) Program for the Prevention of Blindness, nearly 42 million people were affected by severe loss of vision, with cataract being the main cause in 17 million of these cases in 2014. Cataract was the prime cause of blindness in 43.6% of country reports in the same year.

Potential target population in the U.S.

According to Centre for Disease Control and Prevention in 2015, approximately 20.5 million people in the U.S. suffered from cataract, mainly those aged 40 years and older. One of the foremost drivers for ophthalmic femtosecond lasers market is an increasing incidence rate of cataract and rising geriatric population. Among emerging economies, cataract is the major cause of severe visual impairment. World Health Organization carried out a population-based prevalence survey for blindness, across various regions in Africa that are not endemic for trachoma or onchocerciasis, and discovered a blindness rate of around 1%, with cataract accounting for 40%-50% of visual loss cases.

Refractive error can include near-sightedness (myopia), astigmatism or presbyopia, farsightedness (hyperopia). There are several surgical actions for correcting or adjusting eye’s focusing ability by reshaping the cornea, or clear, round dome at the front of your eye. Other procedures involve implanting a lens inside your eye. According to Centres for Disease Control and Prevention (CDC):

Factors impeding ophthalmic femtosecond lasers market growth

Major factors which are hindering the growth of this market are shortage of ophthalmologists. Owing to the presence of key players in North America occupied the leading position in this market with largest share. Over the impending years, the strong focus of these players on R & D, the availability of healthcare infrastructure and a well-established regulatory structure for timely approval of the products are likely to support this regional market to retain its position.

Due to large base of the population, China is expected to emerge as the most attractive domestic market for ophthalmic lasers in Asia Pacific. The Middle East and Africa and Latin America are also projected to witness a considerable rise in their respective markets for ophthalmic lasers in the near future, due to the thriving medical tourism and the low cost of laser eye surgeries in these regions.

Key players operating in the global ophthalmic femtosecond lasers market are IMRA America, Inc., Newport Corporation, Abbott Medical Optics, Alcon, Bausch & Lomb, Carl Zeiss Meditec, and Ziemer Ophthalmic Systems.

Click To Read More On Ophthalmic Femtosecond Lasers Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Medical Radiation Detection, Monitoring, and Safety Market Trends Analysis to 2026

Radiation power is used in various fields such as industries, agriculture, and medicine to benefit humankind. It is widely being used in modern medical treatments, especially for the treatment of cancer, as radiation helps in weakening and destroying particular cancer cells. Modern medicine uses radiation power to obtain diagnostic information about a patient’s specific organ for treatment. Medical imaging helps in diagnosing and detection of diseases at early stages. For instance, exploratory cardiac catheterization is replaced with CT scan for the detection of polyp in the body, which can turn cancerous if it is not detected at the early stage. Medical radiation detection, monitoring, and safety market is segmented into detector type, monitoring products, and safety products. Various types of detectors include solid-state detectors, liquid filled detectors, and scintillators. Solid-state detectors, which provides good accuracy and reproducibility, are used to perform in vivo dosimetry and quality control for both radiotherapy and radiology.

Request For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1802

Medical Radiation Detection, Monitoring, and Safety Market: Drivers

Increasing use of radiation therapy for treatment and diagnosis purposes is expected to fuel growth of medical radiation detection, monitoring, and safety market. According to a study conducted by the National Academics of Sciences Engineering and Medicine in 2016, over 400 million diagnostic examinations and around150 million dental X-ray examinations were performed in the 2015. Increasing prevalence of cancer, rising awareness about use of radiation therapy to treat diseases, and favorable reimbursement policies are other factors that drive growth of medical radiation detection, monitoring, and safety market. According to a study conducted by the U.S. Department of Health & Human Services in 2016, over 80% people in the U.S. have some form of medical insurance. Mergers and acquisitions adopted by major players are also expected to drive growth of medical radiation detection, monitoring, and safety market.

Medical Radiation Detection, Monitoring, and Safety Market: Regional Analysis

North America is expected to witness significant growth in the medical radiation detection, monitoring, and safety market over the forecast period due to new innovations in radiation therapy in the region. For instance, in April 2018, Varian Medical Systems, a U.S.-based company launched 4.0 velocity cancer imaging software with selective internal radiation therapy dosimetry analysis. This software includes Rapidsphere, a module used for Selective Internal Radiation Therapy (SIRT) dosimetry analysis. Rapidsphere provides the ability to understand tumor response and normal tissue toxicity for individual patients receiving SIRT.

Medical Radiation Detection, Monitoring, and Safety Market: Competitive Landscape

Key players operating in the medical radiation detection, monitoring, and safety market include Thermo Fisher Scientific Inc., Canberra Industries Inc., Bar-Ray products Inc., Protech Radiation Safety, ProtecX, Landauer Inc., Mirion Technologies Inc., Amtech Inc., and Biodex Medical Inc.

Medical Radiation Detection, Monitoring, and Safety Market: Taxonomy

The global medical radiation detection, monitoring, and safety market is segmented on the basis of product type, end user, and region.

By Product Type:

By Detectors:

  • Solid-State Detectors
  • Gas-Filled Detector
  • Scintillators

By Monitoring Products:

  • Personal Dosimeters
  • Area Process Monitors
  • Radioactive material Monitor
  • Surface contamination monitors
  • Environment Radiation Monitors
  • Others

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1802

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Osseointegration Implants Market Is Expected To Have The Highest Growth Rate During The Forecast Period 2026

The Global Osseointegration Implants Market size was valued at US$ 5,672.3 million in 2017, and is projected to witness a CAGR of 6.72% over the forecast period (2018 – 2026).

Osseointegration is a process in which a bone anchorage is used on an implant surface which provides a basis to support a prosthesis till that part of the body becomes stronger and supports firmly. These implants are used in various applications such as dental implants, bone and joint replacement procedures, and implants undertaken for amputees. The osseointegration implants are made from material such as titanium, zirconia, ceramic, stainless steel, and others.

Increasing demand for osseointegration implants owing to rising number of joint replacement surgeries among geriatric population is expected to drive market growth. According to the Organisation for Economic Cooperation and Development (OECD), on an average, the rate of hip replacement has increased by 30% between 2000 and 2015, and the rate of knee replacement nearly doubled between 2000 and 2015. Moreover, average incidence of the Hip replacement surgery was 166 per 100,000 population in all 34 OECD countries in 2015.

Moreover, key players are opting for different strategies such as new product launch, acquisitions, partnerships, joint ventures, and agreements to increase their foothold in this market. For instance, in April 2018, Integrum SE launched a new revolutionary OPRA implant system, which will be initially available only in London and would be distributed through London International Patient Services (LIPS) – an organization seeking treatment for international patients.

Growing Number of Joint Replacement Surgeries Among Geriatric Population is Expected to Drive the Osseointegration Implants Market Revenue

Increasing patient population undergoing joint replacement surgeries has boosted growth of the global osseointegration implants market. According to the National Joint Registry (NJR), in 2017, around 992,090 primary total hip replacements, 1,087,611 knee replacements, 4,687 ankle replacements, 30,720 shoulder replacements, and 2,872 elbow replacements were performed in U.K. Moreover, in U.S, around 17,500 new Spinal Cord Injury (SCI) cases are performed annually and an estimated 285,000 people were suffering from SCI in 2017, as per National Spinal Cord Injury Statistical Center (NSCISC).

Increasing demand for cosmetic dentistry, owing to rising prevalence of dental decays is supporting growth of the global osseointegration implants market. According to the U.S. Department of Health and Human Services, the prevalence of total dental caries among the age group aged 2–19 years was 45.8% and it increases with age, from 21.4% (among age group 2–5) to 50.5% (among age group 6–11) and 53.8% (among age group 12–19) in 2016. Moreover, growing disposable incomes in various countries has also influenced growth of the osseointegration implants market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2384

Osseointegration Implants Market Restraints

Although demand for osseointegration implants is increasing worldwide, high-cost associated with the implants or surgery with inadequate reimbursement coverage has restrained growth of the osseointegration implants market. In Australia, the surgical procedure to insert the implant is not covered by the Medicare system and is paid through self-funding or by an individual’s Private Health Insurance as per the Australian Orthotic Prosthetic Association. Moreover, risk and complications associated with osseointegration surgery is one of the major factor hampering growth of the market.

Osseointegration Implants Market – Competitive Landscape

Key players operating in the global osseointegration implants market include Medtronic, Stryker Corporation, Zimmer Biomet Holdings, Smith and Nephew Plc., Straumann AG Group, Integrum SE, Southern Implants, ConMed Corporation and others. Manufacturers in osseointegration implants market are focused on expanding their distribution channels in emerging economies, which offers untapped growth opportunities for the growth of the osseointegration implants market.

Osseointegration Implants Market – Regional Insights

On the basis of region, the global osseointegration implants market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold the leading position in the global osseointegration implants market by 2026, owing to well-established healthcare infrastructure, high adoption rate for technologically advanced products, and growing widespread awareness about minimally invasive surgeries. Moreover, high prevalence of degenerative spinal conditions are fueling growth of the market in this region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Page 1 of 115

Powered by WordPress & Theme by Anders Norén